articleAnnals of SurgeryApr 16, 2025GREEN OA

Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer

MUMichiaki UnnoFMFuyuhiko MotoiYMYutaka MatsuyamaSSSohei SatoiHTHirochika Toyama

Tohoku University · Yamagata University · +12 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Objective

This randomized phase II/III study evaluated the superiority of neoadjuvant therapy with gemcitabine plus S-1 over upfront surgery for patients with resectable pancreatic ductal adenocarcinoma (PDAC).

Background

PDAC is a leading cause of cancer mortality that urgently requires better treatment.

Citation impact

52
total citations
FWCI
41.39
Percentile
100%
References
16
Citations per year

Authors

15

Topics & keywords

Topics
Keywords
  • Medicine
  • Gemcitabine
  • Hazard ratio
  • Internal medicine
  • Pancreatic cancer
  • Neoadjuvant therapy
  • Confidence interval
  • Adenocarcinoma
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.